Conference Menu


개요
쇼트코스
포스터
개최지
문의
참가신청



Media Partners

Bentham Science Logo

Bio-IT-Word_logo

Biospace

eCliniqua

GEN-New Logo

GenomeWeb

Nature_logo

Pharmaphorum

PharmaVoice

Science AAAS

The Scientist


암을 위한 면역조절치료용 항체 - 첫째날



최근 BMS의 Yervoy (ipilumumab)가 승인되고 임상시험을 거쳐 관련 프로그램이 성공함에 따라 항체 기반 암 면역조절제의 개발에 대한 관심이 커지고 있습니다. Therapeutic Antibodies for Cancer에서는 임상 단계 프로그램의 최신 동향을 제공하고, 이와 같은 신규 치료법이 임상시험 디자인과 임상 엔드포인트 선정에 어떻게 영향을 미치는지에 대해 검증합니다. 항체에 의한 표적화를 위한 가장 적절한 면역 조절 전략은 무엇이며, 치료 계획과 신규 치료 형태의 병용을 어디에서 효과적으로 적용할 수 있는지 생각해 봅니다.

첫째날 | 둘째날

2013년 8월 14일(수)

1:40 pm Chairperson's Opening Remarks


1:45 Keynote Presentation:

Immune Monitoring on Pre-Surgical Clinical Trials with a Novel Checkpoint Blockade Agent, Anti-CTLA-4

Padmanee Sharma, M.D., Associate Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center

Biomarker studies for immunotherapies have typically involved monitoring immunologic changes within the systemic circulation; however, recent data indicates that immunological changes within tumor tissues are more likely to predict clinical responses. We conducted a pre-surgical clinical trial with anti-CTLA-4 (ipilimumab) in patients with localized bladder cancer, and identified ICOS as the marker of a subset of effector T cells that is increased in frequency after anti-CTLA-4 therapy. ICOS+ T cells are being explored as pharmacodynamic markers for treatment with anti-CTLA-4 and as novel targets to improve the efficacy of anti-CTLA-4 therapy.


면역 체크포인트 봉쇄 

2:30 Preliminary Clinical Efficacy and Safety of MK-3475 (Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Melanoma

Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute

The programmed death-1 (PD-1) pathway has emerged as an important tumor-evasion mechanism. When PD-1 and PDL-1 join together, the T cell's ability to target the tumor cell is disarmed. Targeting either PD-1 or PDL-1 can stimulate the immune system and enhance T cells' ability to lyse tumor cells.  Similar to, but distinct from cytotoxic T lymphocyte antigen 4 (CTLA-4) this pathway hold promise for many solid tumors.

3:00 Sponsored Presentations (Opportunities Available: Contact Suzanne Carroll at 781-972-5452 or scarroll@healthtech.com for more information)

3:30 Refreshment Break in the Exhibit Hall with Poster Viewing

4:15 Development of Immunomodulatory PD-1 Antibodies in Renal Cell Carcinoma

Lauren Harshman, M.D., Assistant Professor, Dana-Farber Cancer Institute

Targeting the immunosuppressive PD-1 pathway is an area of intense investigation. RCC tumor cells may innately express the ligand of PD-1 or they may acquire it from adaptive immunity. Expression has been associated with worse outcomes. Attempts at countering this host immune system evasion technique are underway with a variety of monoclonal antibodies against PD-1 and its ligands.

4:45 Anti-PD-1 Antibody Therapy for B-Cell Lymphoma

Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

In a phase II trial, the combination of pidilizumab, a humanized anti-PD-1 monoclonal antibody, and rituximab was active and non-toxic in patients with relapsed follicular lymphoma. Activation of T and NK cells was observed in both peripheral blood and tumor microenvironment after pidilizumab therapy and predictors of clinical outcome based on the molecular features of tumor-infiltrating immune cells at baseline were identified.

5:15 AMP-224, A Fusion Protein with Potential to Modulate the PD-1 Pathway

Solomon Langermann, Ph.D., CSO, Amplimmune

AMP-224 is the first recombinant B7-DC-Fc fusion protein tested in patients that binds to and modulates the PD-1 axis through a unique MOA. The MOA hypothesis for AMP-224 is depletion of PD-1 high expressing T-cells representing exhausted effector cells. The pharmacodynamic readouts obtained to date demonstrate that AMP-224 is biologically active in its target patient population. Data from the trial has been used to establish hypotheses regarding the characteristics of patients most likely to respond clinically to AMP-224 treatment.

5:45 Close of Sessions




Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English

Catalog


국제컨퍼런스
Gii Event
이벤트 캘린더
메일링 서비스
메일링 서비스

한국어 공식사이트 운영 : Cambridge Healthtech Institute 파트너 (주)글로벌인포메이션